Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and

docun	nents given to ASX become ASX's property a	and may be made public.
Introduc 04/03/1		01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
	of entity  Minerals Limited	
AVZ	Willierais Liffliteu	
ABN		
81 1	25 176 703	
We (	the entity) give ASX the following in	oformation.
	t 1 - All issues oust complete the relevant sections (attach s	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Performance Rights
2	Number of teasurities issued on to	C 000 000
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	6,000,000
2	Deignal and the tangential	4) 2 000 000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	<ol> <li>3,000,000 expiring 1 November 2022 with various vesting conditions</li> <li>3,000,000 expiring 11 November 2020 with various vesting conditions</li> </ol>

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	No
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued to an employee and a contractor of the Company under the Company's Performance Rights Plan
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2018
6c	Number of *securities issued without security holder approval under rule 7.1	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 = 31,062,398 Rule 7.1A = 204,366,161	
7	†Issue dates	14 November 2019	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	17 NOVEHIDEI 2013	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX	2,304,148,459	Ordinary Shares
	(including the *securities in section 2 if applicable)	203,649,049	Listed Options exercisable at 3 cents expiring 24 May 2020

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	†Class
3,600,000	Performance Rights with various vesting conditions
26,100,000	Performance Rights with various vesting conditions expiring 3 December 2021
8,000,000	Performance Rights with various vesting conditions expiring 2 June 2022
3,000,000	Performance Rights with various vesting conditions expiring 11 November 2020
3,000,000	Performance Rights with various vesting conditions expiring 1 November 2022
4,500,000 (Subject to shareholders approval)	Performance Rights with various vesting conditions expiring 3 December 2021
30,000,000	Unlisted Options exercisable at 30.5 cents expiring 28 February 2020
1,000,000	Unlisted Options exercisable at 4.75 cents expiring 5 March 2021
5,000,000	Unlisted Options exercisable at 5.7 cents expiring 5 Sept 2021
5,000,000	Unlisted Options exercisable at 6.65 cents expiring 5 March 2022

Appendix 3B Page 4 04/03/2013

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable
Part	2 - Pro rata issue	
11	Is security holder approval required?	-
12	Is the issue renounceable or non-renounceable?	-
13	Ratio in which the *securities will be offered	-
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	-
15	*Record date to determine entitlements	-
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	-
17	Policy for deciding entitlements in relation to fractions	-
18	Names of countries in which the entity has security holders who will not be sent new offer documents	-
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	-

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

20	Names of any underwriters	-
21	Amount of any underwriting fee or commission	-
22	Names of any brokers to the issue	-
23	Fee or commission payable to the broker to the issue	-
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	-
25	If the issue is contingent on security holders' approval, the date of the meeting	-
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	-
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	-
28	Date rights trading will begin (if applicable)	-
29	Date rights trading will end (if applicable)	-
30	How do security holders sell their entitlements <i>in full</i> through a broker?	-
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	-

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	their	do security holders dispose of entitlements (except by sale gh a broker)?	-
33	*Issue	date	-
		Quotation of securit	
34	Type o	of †securities ne)	
(a)		*Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
Entiti	es tha	nt have ticked box 34(a)	
Addition	onal se	curities forming a new class	s of securities
Tick to docume		you are providing the informat	tion or
35		• •	securities, the names of the 20 largest holders of the e number and percentage of additional *securities held
36			y securities, a distribution schedule of the additional nber of holders in the categories
37		A copy of any trust deed for the	ne additional †securities

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

## Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	-	
39	*Class of *securities for which quotation is sought	-	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	-	
	If the additional *securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	-	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	-	

Appendix 3B Page 8 04/03/2013

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will
    not require disclosure under section 707(3) or section 1012C(6) of the
    Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

...... Date: 15 November 2019

Sign here:

pany secretary)

Print name: Leonard Math

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid †ordinary securities on issue 12 months before the †issue date or date of agreement to issue	1,868,461,449	
<ul> <li>Number of fully paid †ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid †ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid †ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid †ordinary securities cancelled during</li> </ul>	19/07/2018 Vesting of Performance Rights 20,000,000 25/02/2019 Share Purchase Plan 137,250,166 07/06/2019 Exercise of Options 4,000,000 12/07/2019 Vesting of Performance Rights 13,950,000	
that 12 month period  "A"	2,043,661,615	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	306,549,242	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<i>Insert</i> number of *equity securities issued or	257,486,844 Shares (Placement – 4 March 2019)	
agreed to be issued in that 12 month period not counting those issued:	15,000,000 Unlisted Options (4 March 2019)	
Under an exception in rule 7.2	3,000,000 Shares (Placement – 5 July 2019)	
Under rule 7.1A		
<ul> <li>With security holder approval under rule</li> <li>7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>		
"C"	275,486,844	
Step 4: Subtract "C" from ["A" x "B"] to under rule 7.1	calculate remaining placement capacity	
"A" x 0.15	306,549,242	
Note: number must be same as shown in Step 2		
Subtract "C"	275,486,844	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	31,062,398	
	[Note: this is the remaining placement capacity under rule 7.1]	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

### Part 2

	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" 2,043,661,615		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	204,366,161	
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	202,971,161	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	202,971,161	
	Note: this is the remaining placement capacity under rule 7.1A	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.